Ann: QRxPharma Updates MOXDUO NDA Review , page-2

Interesting announcement.
I find it somewhat disappointing that with so much at stake with the re-submission, the company has neglected to fine-tune their data until 3 weeks out of the meeting. For something as simple as timing the collection of oxygen readings to be over-looked is not a good sign of confidence for me..
Data should have been checked over a thousand times by now.
Will see what tomorrow brings lol.